Today: The Astrazeneca PLC (AZN) Stock Rating Reaffirmed by Shore Capital

The Astrazeneca PLC (AZN) Stock Rating Reaffirmed by Shore Capital

Astrazeneca PLC (NYSE:AZN)‘s stock had its “hold” rating reiterated by stock analysts at Shore Capital in a research report issued to clients and investors on Saturday.

Several other equities research analysts have also recently issued reports on the company. Bank of America Corp. reissued a “buy” rating and set a $36.65 target price on shares of Astrazeneca PLC in a research note on Monday, July 18th. Citigroup Inc. reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Friday, September 23rd. Berenberg Bank reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Sunday, September 11th. Beaufort Securities reaffirmed a “hold” rating on shares of Astrazeneca PLC in a research note on Friday, August 26th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Astrazeneca PLC in a research note on Sunday, July 31st. Three analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Astrazeneca PLC currently has an average rating of “Buy” and a consensus target price of $37.44.

Astrazeneca PLC (NYSE:AZN) opened at 32.29 on Friday. Astrazeneca PLC has a 12 month low of $26.97 and a 12 month high of $35.04. The company’s 50-day moving average price is $33.23 and its 200 day moving average price is $30.79. The firm has a market capitalization of $81.69 billion, a price-to-earnings ratio of 36.90 and a beta of 0.75.

10/08/astrazeneca-plc-azn-stock-rating-reaffirmed-by-shore-capital-2.html

Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.76 by $0.07. The company earned $5.60 billion during the quarter, compared to analysts’ expectations of $5.56 billion. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The firm’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.21 earnings per share. Analysts predict that Astrazeneca PLC will post $2.97 EPS for the current year.

The business also recently declared a dividend, which was paid on Monday, September 12th. Investors of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 78.29%.

Institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. boosted its position in shares of Astrazeneca PLC by 0.3% in the first quarter. JPMorgan Chase & Co. now owns 2,325,462 shares of the company’s stock valued at $65,485,000 after buying an additional 6,027 shares during the period. Integrated Investment Consultants LLC boosted its position in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock valued at $144,000 after buying an additional 275 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Astrazeneca PLC by 3.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 34,217 shares of the company’s stock valued at $964,000 after buying an additional 1,027 shares during the period. Fisher Asset Management LLC boosted its position in shares of Astrazeneca PLC by 45.2% in the second quarter. Fisher Asset Management LLC now owns 338,979 shares of the company’s stock valued at $10,159,000 after buying an additional 105,570 shares during the period. Finally, Garrison Financial Corp boosted its position in shares of Astrazeneca PLC by 1.1% in the second quarter. Garrison Financial Corp now owns 18,992 shares of the company’s stock valued at $573,000 after buying an additional 205 shares during the period. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Astrazeneca PLC

Related posts

Leave a Comment